The Associations Between Fasting Plasma Glucose Levels and Mortality of SFTS in Patients

Yin Zhang  
First Affiliated hospital of Anhui Medical University

Yu Zhang  
First Affiliated hospital of Anhui Medical University

Yuanhong Xu  
First Affiliated hospital of Anhui Medical University

Ying Huang (✉ huangying_ah2007@sina.com)  
First Affiliated hospital of Anhui Medical University

Research Article

Keywords: SFTSV, cohort study, fasting plasma glucose, outcomes, mortality

Posted Date: February 24th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-228628/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at BMC Infectious Diseases on August 5th, 2021. See the published version at https://doi.org/10.1186/s12879-021-06463-3.
The associations between fasting plasma glucose levels and mortality of SFTS in patients

Yin Zhang 1, Yu Zhang 1, Yuanhong Xu 1, Ying Huang 1

1 Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China

Correspondence

Ying Huang, Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Rd, Hefei, Anhui Province, China. Email: huangying_ah2007@sina.com
The associations between fasting plasma glucose levels and mortality of SFTS in patients

Abstract

Objective To identify the correlation between the level of at-admission fasting plasma glucose (FPG) with poor outcomes in hospitalized patients suffering from severe fever with thrombocytopenia syndrome (SFTS).

Methods Between April 1 and December 1, 2020, the list of hospitalized patients affected with SFTS infection was provided by the Infectious Disease Department at First Affiliated Hospital of Anhui Medical University, followed by the collection of information i.e., gender, age, diabetic history and the level of FPG on admission.

Results In this study, a total of 77 patients were included and were categorized into three groups (<5.6, 5.6–6.9, and ≥7.0 mmol/l) on the basis of their glucose level in the blood. The obtained results revealed that among three groups considerable variations were observed in leukocytes, FPG, D-Dimer, aspartate aminotransferase (AST), tumor necrosis factor-α (TNF-α), fibrin degradation products (FDP), and interleukin (IL)-10 level. Correlation analysis indicated a linear negative correlation between PLT and FPG (r = −0.28, P = 0.01), however, a linear positive correlation was observed between AST, IL10, D-Dimer, and FDP levels and FPG (P-value < 0.05).

Conclusions Elevated level of FPG has been correlated with hypercoagulability, inflammation, and lower PLT in SFTS patients. The measurement of FPG level can help in evaluating the inflammatory process, hypercoagulability, and prognosis of patients suffering from SFTS.

Keywords: SFTSV, cohort study, fasting plasma glucose, outcomes, mortality
Introduction

Severe fever with thrombocytopenia syndrome (SFTS) is an infectious disease. For the first time, the infection was reported in China (2011) and then the cases were appeared in South Korea and Japan [1-3]. SFTS has been caused by SFTS bunyavirus (SFTSV) and its transmission occurs through tick bites while sometimes, it can be transmitted through aerosol and blood transfer [4, 5]. Humans of all ages can be infected by SFTS but the people of old ages \( i.e., \ 50 \geq \) are at higher risk due to compromised immune systems [6]. The patients infected with SFTS may be asymptomatic or symptomatic with a common febrile illness that can lead to hypovolemic shock and failure of multiple organs [7]. A mortality rate of 50% has been reported for SFTS [8].

The earlier studies have revealed that the mortality rate in SFTS has a positive correlation with diabetes. However, the association of FPG with the severity and fatality rate of the disease has not been revealed. In this view, it is important to identify whether FPG can be used as a prognostic marker in SFTS for early detection of severe cases and reduce the death rate.

In the current study, the clinical data of 77 patients in First Affiliated Hospital of Anhui Medical University were evaluated to identify the FPG predictive value in the severity and fatality in SFTS.

Materials and methods

Study design and the collection of data

In the current study, the clinical data of patients (affected with SFTS) was collected from the first affiliated hospital of Anhui Medical University between 1st April 2020 and 1st December 2020. Eighty-one patients (suffering from SFTS) were admitted into the hospital in which 4 patients were ruled out for the underlined reasons: (1) no FPG data available at admission (2) having previously diagnosed diabetes. All patients were classified into three groups on the basis of WHO guidelines in terms of FPG at admission (<5.6, 5.6–6.9, and \( \geq \)7.0 mmol/l).

The approval for this study was provided by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University. In this retrospective study, informed consent was waived by using anonymous clinical data.
**Laboratory examination**

Regular blood tests were carried out in all patients, including blood routine test, coagulation profile measurement, CRE (creatinine), FPG, ALT (alanine aminotransferase), AST (aspartate aminotransferase), CK (creatine kinase), and LDH (lactate dehydrogenase) levels. Inflammatory markers *i.e.*, PCT (procalcitonin), CRP (C-reactive protein), TNF-α (tumor necrosis factor-α), and interleukins (IL-1β, IL-2R, IL-6, IL-8, and IL-10) were also determined in all patients. RT-PCR was employed for the detection of SFTSV.

**Statistical Analysis**

The statistical analysis was conducted via SPSS (version 24.0) and Graphpad Prism (version 9.0). In descriptive statistics, the median (IQR) was for continuous variables, and counts and proportions were for categorical variables. Chi-square or Mann-Whitney U test was used for evaluating variations in parametric and non-parametric demographic data in SFTS survivors and non-survivors. For continuous variables, the Kruskal Wallis test was conducted to compare three categories (FPG<5.6, 5.6–6.9, and ≥7.0 mmol/l) while Fisher's exact or chi-square test was carried out for categorical variables. The correlation between the level of FPG and variables was evaluated by Spearman’s bivariate simple correlation analysis. Results were regarded to be statistically considerable at a two-tailed P value of less than 0.05.

**Results**

SFTSV RNA tests were carried out in which a total of 77 patients were found to be SFTS positive. In SFTS positive patient's there were 35 males and 42 females. 16 of 77 cases died and their median duration from hospital admission to death was 4.5 days. 61 of 77 cases were discharged and their median duration from hospital admission to discharge was 12 days. Herein, our study reveals a significant comparison between the clinical characteristics of deceased and survivor patients.

According to the obtained data, the survivors were comparatively younger than those non-survivors patients. Non-survivors had relatively elevated FPG levels *i.e.*, 10.1 vs. 6.9, *P* = 0.015, and shorter hospital stay (4.5 vs 12.0, *P*<0.001) as compared to the survivor's patients. Based on their biochemical considerations, non-survivors were found to be with elevated level of AST
(457 vs. 120 U/L, P= 0.005), ALT (97 vs. 75 U/L, P= 0.034), CRE (94.2 vs. 67.5 umol/L, P = 0.001) and LDH (1720 vs. 827 U/L, P=0.002) levels. Based on the inflammatory biomarkers, the non-survivors had significantly higher PCT (0.54 vs 0.11 ng/ml, P = 0.001), IL-1β (22.7 vs 22.7 pg / ml, P <0.001), IL-2R (1714 vs.1106 U/ml, P = 0.001), IL-6 (68.7 vs. 10.8 pg / ml, P <0.001), IL-8 (73.5 vs. 20.5 pg/ml, P = 0.001), IL-10 (117 vs.36 pg / ml, P <0.001) and TNF-α (47.4 vs. 18.4 pg/ml, P <0.001, Table 1).

Table 1 The clinical characteristics between survivors and non-survivors.

|                        | Survivors N = 61 | Non-survivors N = 16 | P values |
|------------------------|------------------|----------------------|----------|
| Age, years, median (IQR) | 63 (55-69)       | 66 (61-72)           | 0.26     |
| Gender (Male/Female)    | 34/27            | 8/8                  | 0.682    |
| Time from onset to admission (days) | 5 (4-7) | 5 (5-7) | 0.969 |
| Duration of hospital admission (days) | 12 (9-16) | 4.5 (1.2-7.7) | <0.001 |
| Fasting plasma glucose (mmol/L) | 6.9 (5.3-9.5) | 10.1 (12.9) | 0.015 |
| Leukocytes (×10⁹/L)     | 2.32 (1.6-3.9)   | 2.3 (1.4-3.5)       | 0.551    |
| Neutrophils (×10⁹/L)    | 1.3 (0.8-2.3)    | 1.2 (0.8-2.3)       | 0.90     |
| Platelet (×10⁹/L)       | 46 (34-68)       | 40 (25-52)          | 0.189    |
| Procalcitonin (ng/ml)   | 0.11 (0.05-0.22) | 0.54 (0.15-0.89)    | 0.001    |
| C-reactive protein (mg/L) | 3.1 (0.8-9.2) | 4.7 (2.0-12.8) | 0.177 |
| Aspartate aminotransferase (U/L) | 120 (89.5-232) | 457 (128-706) | 0.005 |
| Alanine aminotransferase (U/L) | 75 (43.5-92) | 97 (59-178) | 0.034 |
| Creatinine (μmol/L)     | 67.5 (58-88.1)   | 94.2 (76-166)       | 0.001    |
| Lactate dehydrogenase (U/L) | 827 (562-1556) | 1720 (1008-5761)  | 0.002    |
| Creatine kinase (U/L)   | 316 (116-731)    | 580 (185-3563)      | 0.096    |
| PT, secs.               | 13.5 (12.8-13.9) | 13.6 (12.8-15.2)    | 0.397    |
| Variables                                      | All (n = 77) | Group A (n = 19) | Group B (n = 18) | Group C (n = 40) | p-Value |
|-----------------------------------------------|-------------|-----------------|-----------------|-----------------|--------|
| APTT, secs.                                   | 50.4 (42.8-54.8) | 67.7 (54.4-85.5) | <0.001          |
| D-Dimer (μg/mL)                               | 1.87 (1.27-3.61) | 6.7 (2.8-15.7)  | <0.001          |
| Fibrin degradation product (μg/mL)            | 5.98 (3.77-12.3) | 19.7 (8.9-63.2) | 0.001           |
| Interleukin-1β (pg/ml)                        | 8.1 (5.0-13.5)   | 22.7 (10.9-36.0) | <0.001          |
| Interleukin-2R (U/ml)                         | 1106 (841-1381)  | 1714 (1267-2803) | 0.001           |
| Interleukin-6 (pg/ml)                         | 10.8 (5.0-16.3)   | 68.7 (20.4-140.0) | <0.001          |
| Interleukin-8 (pg/ml)                         | 20.5 (14.9-32.4)  | 73.5 (34.4-232.5) | 0.001           |
| Interleukin-10 (pg/ml)                        | 36 (10.4-63.6)    | 117 (53.8-275.5) | <0.001          |
| Tumor necrosis factor-α (pg/ml)               | 18.4 (14.8-24.0)  | 47.4 (27.3-116.3) | <0.001          |

Based on the FPG levels, the selected population was further categorized into three classes. The percent of deaths were 5.3%, 22.2%, and 27.5% in groups A, B, and C, respectively, as presented in table 2. Among these three groups; FPG, AST, D-Dimer, FDP, IL-10, TNF-α levels, and leukocyte counts were found to be considerably varied (all P<0.05). As compared with those in group A, leukocyte counts were found to be considerably lower, while AST, D-Dimer, FDP, IL-10, and TNF-α concentration were recorded comparatively higher (all P<0.05).

Table 2 Comparison of laboratory parameters and baseline characteristics among the three groups of SFTS patients.

| Variables                        | All (n = 77) | Group A (n = 19) | Group B (n = 18) | Group C (n = 40) | p-Value |
|----------------------------------|-------------|-----------------|-----------------|-----------------|--------|
| Age, years, median (IQR)        | 64.0 (56.0-69.0) | 62.0 (51.0-68.0) | 58.5 (53.8-70.0) | 66.0 (63.0-70.0) | 0.059  |
| Sex                              |             |                 |                 |                 |        |
| Female, n (%)                   | 42 (54.5)   | 8 (42.1)        | 8 (44.4)        | 26 (65.0)       | 0.158  |
| Male, n (%)                     | 35 (45.5)   | 11 (57.9)       | 10 (55.6)       | 14 (35.0)       |        |
| Onset symptoms                  |             |                 |                 |                 |        |
| Fever, n (%)                    | 75 (97.4)   | 19 (100)        | 17 (94.4)       | 39 (97.5)       | 0.568  |
| Cough, n (%)                    | 32 (41.6)   | 6 (31.6)        | 8 (44.4)        | 18 (45.0)       | 0.144  |
| Condition                        | Group A   | Group B   | Group C   | Group D   | Group E   | p-Value |
|---------------------------------|-----------|-----------|-----------|-----------|-----------|---------|
| Expectoration, n (%)            | 24 (31.2) | 3 (15.8)  | 5 (27.8)  | 16 (40.0) | 0.162     |
| Muscular soreness, n (%)        | 39 (50.6) | 11 (57.9) | 12 (66.7) | 16 (40.0) | 0.131     |
| Fatigue, n (%)                  | 58 (75.3) | 15 (78.9) | 11 (61.1) | 32 (80.0) | 0.278     |
| Diarrhoea, n (%)                | 37 (48.1) | 7 (36.8)  | 10 (55.6) | 20 (50.0) | 0.491     |
| Time from onset to admission, median (IQR), d | 5.0 (4.5-7.0) | 7.0 (5.0-8.0) | 5.0 (4.0-7.0) | 5.0 (5.0-7.0) | 0.357     |
| FPG (mmol/L)                    | 7.38 (5.58-10.29) | 4.91 (4.42-5.22) | 6.16 (5.96-6.54) | 10.23 (8.71-12.93) | <0.01     |
| Leukocytes (×10^9/L)            | 2.32 (1.56-3.69) | 4.02 (1.63-5.07) | 2.80 (1.93-3.34) | 1.94 (1.30-2.93) | 0.026     |
| Neutrophils (×10^9/L)           | 1.33 (0.82-2.34) | 2.06 (0.87-2.73) | 1.38 (0.94-2.07) | 1.12 (0.73-1.98) | 0.159     |
| Platelet (×10^9/L)              | 45.0 (34.0-64.5) | 54.0 (34.0-69.0) | 45.0 (40.7-73.0) | 40.5 (30.0-59.0) | 0.108     |
| CRP (mg/L)                      | 3.4 (1.04-9.64) | 3.9 (0.8-10.43) | 3.57 (0.69-6.57) | 3.1 (1.15-10.17) | 0.635     |
| Procalcitonin (mg/L)            | 0.15 (0.06-0.35) | 0.11 (0.05-0.45) | 0.09 (0.06-0.15) | 0.20 (0.11-0.37) | 0.067     |
| IL-1β (pg/mL)                   | 9.36 (5.0-16.0) | 6.85 (5.0-11.95) | 9.02 (5.0-18.8) | 9.74 (5.0-16.6) | 0.489     |
| IL-2R (U/mL)                    | 1208 (903-1578) | 955 (748-1353) | 1151 (941-1369) | 1352 (1031-1678) | 0.106     |
| IL-6 (pg/mL)                    | 12.6 (5.99-32.6) | 7.58 (3.2-24.0) | 12.8 (6.63-59.9) | 13.0 (7.14-34.3) | 0.172     |
| IL-8 (pg/mL)                    | 24.1 (15.7-42.8) | 17.3 (12.8-28.3) | 25.5 (17.05-50.5) | 27.2 (17.7-47.9) | 0.057     |
| IL-10 (pg/mL)                   | 45.9 (12.3-96.8) | 11.65 (7.2-27.3) | 24.9 (11.0-56.9) | 61.7 (43.2-139.0) | 0.0001    |
| TNF-α (pg/mL)                   | 20.0 (15.2-33.3) | 18.2 (13.3-27.0) | 16.6 (14.2-25.5) | 23.2 (17.0-43.0) | 0.042     |
| AST (U/L)                       | 158 (92.0-306.5) | 110 (84.0-147) | 125.5 (98.0-204.7) | 227.5 (101.7-425.5) | 0.021     |
| ALT (U/L)                       | 83.0 (78.0 (39.0-89.0)) | 78.0 (39.0-89.0) | 69.5 (44.5-98.5) | 86.5 (44.5-98.5) | 0.422     |
CRE (μmol/L) 72.0 (59.5-93.1) 72.8 (53.6-86.2) 83.9 (59.5-101.8) 71.5 (60.1-91.3) 0.592
LDH (U/L) 951 (594-1733) 723 (531-1314) 798 (500-1353) 1177 (754-2322) 0.059
CK (U/L) 382 (121-887) 239 (93-686) 362 (107-1679) 406 (158-1007) 0.427
PT (S) 13.5 (12.8-14.0) 13.7 (12.7-14.5) 13.3 (12.8-13.6) 13.5 (12.7-14.2) 0.477
APTT (S) 51.8 (46.3-59.3) 45.7 (39.9-58.9) 51.2 (48.7-54.1) 54.5 (47.5-65.3) 0.184
FIB (g/L) 2.79 (2.43-3.45) 2.98 (2.6-3.85) 2.77 (2.42-3.25) 2.78 (2.35-3.46) 0.429
D-Dimer (μg/ml) 2.55 (1.38-6.61) 1.54 (1.24-1.89) 2.47 (1.44-3.34) 3.84 (1.75-8.93) 0.003
FDP (μg/ml) 6.42 (4.09-15.45) 4.92 (3.55-5.78) 6.28 (4.03-11.31) 11.79 (6.01-30.58) 0.002
Secondary infection, n (%) 35 (45.5) 8 (42.1) 5 (27.8) 22 (55.0) 0.148
Median length of in-hospital stay (days), median (IQR) 11.0 (8.0-15.0) 10.0 (9.0-12.0) 10.5 (6.5-15.0) 11.0 (8.0-16.0) 0.465
Mortality (n, %) 20.8% 5.3% 22.2% 27.5% 0.14

According to the pairwise comparison, the difference between groups B and C was statistically significant in terms of IL-10 levels, as shown in Fig. 1. Spearman’s bivariate simple correlation analysis revealed that the concentration of FBG has a positive correlation with AST (r = 0.234, P = 0.04), D-Dimer (r = 0.411, P < 0.01), FDP (r = 0.39, P <0.01) and IL-10 (r = 0.363, P <0.01) levels. Moreover, the levels of FBG were found to be negatively correlated with PLT levels (r = −0.283, P = 0.01) as shown in Fig. 2.
Fig. 1 Inflammatory factors in blood and FPG among the three groups

Fig. 2 Correlation analysis of inflammatory factors, platelet, and FPG level
Discussion

In hospitalized patients, the admission glucose level is considerably associated with outcomes, and a high level of glucose predicts elevated lengths of stay, failure of organs, and increased mortality. For instance, hyperglycemia predicts raised mortality and the development of organ dysfunction in patients with sepsis [9]. The elevated level of glucose may evaluate prehospitalization comorbidity, including diabetes or side effects of drugs i.e., corticosteroids, or may characterize acute stress reactions correlated with severe illness. Elevated glucose level results in an osmotic diuresis with hypovolemia and loss of electrolyte and can attenuate immune responses. Hyperglycemia activates the formation of advanced glycation end products which interacts with the lipids, proteins, and cell membrane. Interaction with the cellular membrane can result in endothelial dysfunction. Infection may cause stress and stimulation of the sympathetic nervous system. The pancreas can also be attacked by the SFTS virus. Due to these factors the patients infected with SFTS might be more susceptible to hyperglycemia. In this view, the level of glucose pattern in patients was analyzed to evaluate the associated risk factor of hyperglycemia.

Herein, we evaluated the influence of FPG level on the prognosis of non-diabetic patients, associated with SFTS. Survivors showed a reduced level of FPG when compared with non-survivors. Besides, survivors had a low level of proinflammatory cytokines than non-survivors, which suggests that cytokine storm and sustained inflammatory effect may be linked with the severity of SFTS. According to the recently reported data, SFTS positive patients had an elevated concentration of G-CSF, MCP1, IP10, IL1-RA, IL6, and IL10 [10-11]. It has been reported that hyperglycemia is correlated with considerably increasing oxidative stress, and level of inflammatory cytokines, and drastically altering the balance between inflammatory and anti-inflammatory cytokines [12]. Acute hyperglycemic condition is associated with the alteration of innate immune responses, which may up to some extent demonstrate the poor outcomes in those SFTS positive individuals who developed hyperglycemia [13]. This study also analyzed that patients with an elevated level of FPG had a comparatively high concentration of inflammatory cytokines such as TNF-α and IL-10. Moreover, in comparison with the other two groups, patients in the high FPG group were found to be with low leukocyte counts. The underlined results revealed that increase FPG is correlated with immunity and infection in SFTS positive and
non-diabetic patients. One of the possible reason of infection development is stress-induced hyperglycemia because the elevated concentration of glucose negatively affect the essential components of the innate immune system [14], and can induce aberrant glycosylation of proteins, enzymes and immunoglobulins, followed altering the adaptive immune system [15]. High glucose concentration decreases the migration and phagocytosis ability of neutrophils [13].

In this study, out of 77 SFTS positive patients, 59 patients were found to be with the pancreatic injury. These patients were found to be comparatively more vulnerable to diarrhea and anorexia. The concentration of amylase and lipase were in the range of 34 to 681 U/L, and 301 to 2000 U/L, respectively. Forty-seven of the patients had abnormal glucose levels. According to these results, the primary target of the virus is maybe the pancreas, followed by causing series injury, leading to a decreased level of insulin production. The interaction of SFTS with the pancreatic endocrine system complicates the situation for SFTS positive patients.

Previously reported studies demonstrated that some viruses can directly invade on beta cells of the pancreas [16]. Similarly, several latest studies reveal that the viral replicating process takes place in the mammalian pancreas, followed by eliciting inflammation-associated responses but does not cause diabetes [17]. Mechanical shock can also result in hypoxic pancreatic damage [18]. This supports the evidence that pancreatic injury is higher among patients with more severe disease. We do not believe that the possible relate between SFTS infection and pancreatic function should be ruled out although we were incapable of identifying diabetogenic activity for the SFTS virus.

In the current study, serum samples of SFTS positive patients revealed an elevated level of aspartate and alanine aminotransferases, creatine kinase, creatinine, D-dimer, lactate dehydrogenase, fibrin degradation products, and activated partial-thromboplastin time (APTT). These aberrantly altered parameters are indicative of pathological lesions in the heart, kidney, liver, and coagulation systems of SFTS positive patients. In SFTS, hepatocytes were found to be not infected with SFTSV, while several SFTSV-NP antigen-positive cells were detected in the liver [19-20]. In this view, it is demonstrated that in SFTS positive patients, the liver damage might be due to a subordinate pathological event rather than due to direct destruction caused by SFTSV.
As with other viral hemorrhagic fevers, critical features of SFTS evident in applicable animal models include damage to secondary lymphoid organs, widespread coagulopathy, and induction of a ‘cytokine storm’ that may lead to septic shock [21]. Besides, elevated permeability of endothelium results in endothelial damaging that leads to death. Endothelial damage triggers the intrinsic cascade of coagulation and also activates the aggregation of platelet adhesion and degranulation which imbalance homeostasis. Finally, the underlined conditions result in disseminated intravascular coagulation (DIC) and diffuse hemorrhage because of elevated consumption level of coagulation factors. In SFTS, the liver function has been impaired due to the cytopathic effect of viruses which results in decreasing the formation of plasma coagulation factors, as the underlined factors are mostly formed in the liver.

The present study has some limitations. Firstly, this is a retrospective study of a single-center dataset while the sample size is also small. Therefore, further conformation is necessary along with a multi-centered study, larger sample size, and patients of multi-ethnic origins. Secondly, the multivariate regression analysis might not be conducted to evaluate whether the elevated FPG level was an independent risk factor for the mortality in patients affected with SFTS due to many deaths. Thirdly, whether the elevated FPG level in patients (affected with SFTS) is transient is not clear due to the short time of observation and needs further evaluation. Eventually, our sample size limited the glycemic target research for SFTS patients with hyperglycemia.

In summary, at-admission hyperglycemia is a bad prognostic indicator and needs proper detection and cure and this postulate has been supported by our data. In the present study, hyperglycemia was appeared to be a risk factor for deaths in SFTS affected patients but still, there is a lack of clarity regarding the exact mechanism and it is also unclear that whether significantly controlling glucose level would result in a good prognosis in patients (affected with SFTS). So, Glycemic testing has been suggested for all patients (affected with SFTS) because mostly SFTS patients are susceptible to glucose metabolic disorders. FPG may trigger the evaluation of the prognosis and early involvement of hyperglycemia to enhance the overall outcomes in SFTS treatment.

References
1. Yu XJ, Liang MF, Zhang SY, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011 Apr 21;364(16):1523-32.

2. Kim KH, Yi J, Kim G, Choi SJ, Jun KI, Kim NH, Choe PG, Kim NJ, Lee JK, Oh MD. Severe fever with thrombocytopenia syndrome, South Korea, 2012. Emerg Infect Dis. 2013;19(11):1892–1894.

3. Takahashi T, Maeda K, Suzuki T, Ishido A, Shigeoka T, Tominaga T, Kamei T, Honda M, Ninomiya D, Sakai T, et al. The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan. J Infect Dis. 2014;209(6):816–827.

4. Gai Z, Liang M, Zhang Y, Zhang S, Jin C, Wang SW, Sun L, Zhou N, Zhang Q, Sun Y, Ding SJ, Li C, Gu W, Zhang F, Wang Y, Bian P, Li X, Wang Z, Song X, Wang X, Xu A, Bi Z, Chen S, Li D. Person-to-person transmission of severe fever with thrombocytopenia syndrome bunyavirus through blood contact. Clin Infect Dis. 2012 Jan 15;54(2):249-52.

5. Gong Z, Gu S, Zhang Y, Sun J, Wu X, Ling F, Shi W, Zhang P, Li D, Mao H, Zhang L, Wen D, Zhou B, Zhang H, Huang Y, Zhang R, Jiang J, Lin J, Xia S, Chen E, Chen Z. Probable aerosol transmission of severe fever with thrombocytopenia syndrome virus in southeastern China. Clin Microbiol Infect. 2015;21(12):1115-20.

6. Ding S, Niu G, Xu X, et al. Age is a critical risk factor for severe fever with thrombocytopenia syndrome. PLoS One. 2014;9(11):e111736.

7. Zhang Y, Miao W, Xu Y, Huang Y. Severe fever with thrombocytopenia syndrome in Hefei: Clinical features, risk factors, and ribavirin therapeutic efficacy. J Med Virol. 2020 Sep 23. doi: 10.1002/jmv.26544. Epub ahead of print.

8. Lei XY, Liu MM, Yu XJ. Severe fever with thrombocytopenia syndrome and its pathogen SFTSV. Microbes Infect. 2015;17(2):149-54.

9. Yu WK, Li WQ, Li N, Li JS. Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counterregulatory hormone concentrations. World J Gastroenterol. 2003;9(8):1824-7.
10. Yong-Zhen Zhang, Yong-Wen He, Yong-An Dai, et al. Hemorrhagic Fever Caused by a Novel Bunyavirus in China: Pathogenesis and Correlates of Fatal Outcome. Clinical Infectious Diseases. 2012;54(4):527–533.

11. Yulan Sun, Cong Jin, Faxian Zhan, et al. Host Cytokine Storm Is Associated With Disease Severity of Severe Fever With Thrombocytopenia Syndrome, The Journal of Infectious Diseases. 2012;206(7):1085–1094.

12. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106(16):2067-72.

13. Jafar N, Edriss H, Nugent K. The Effect of Short-Term Hyperglycemia on the Innate Immune System. Am J Med Sci. 2016;351(2):201-11.

14. M. Turina, D.E. Fry, H.C. Polk Jr. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit Care Med. 2005;33(7):1624-1633.

15. R.R. Ng, A. Myat Oo, W. Liu, T.E. Tan, L.K. Ti, S.T. Chew. Changing glucose control target and risk of surgical site infection in a Southeast Asian population. J Thorac Cardiovasc Surg. 2015;149(1):323-328.

16. Jaeckel E, Manns M, Von Herrath M. Viruses and diabetes. Ann N Y Acad Sci. 2002;958:7-25.

17. Ilaria Capua, Alessia Mercalli, Aurora Romero-Tejeda, Matteo S Pizzuto, Samantha Kasloff, Valeria Sordi, Ilaria Marzinotto, Vito Lampasona, Elisa Vicenzi, Cristian De Battisti, Riccardo Bonfanti, Andrea Rigamonti, Calogero Terregino, Claudio Doglioni, Giovanni Cattoli, Lorenzo Piemonti. Study of 2009 H1N1 Pandemic Influenza Virus as a Possible Causative Agent of Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2018;103(12):4343–4356.

18. Muniraj T, Dang S, Pitchumoni CS. PANCREATITIS OR NOT?--Elevated lipase and amylase in ICU patients. J Crit Care. 2015;30(6):1370-5.

19. Li S, Li Y, Wang Q, et al. Multiple organ involvement in severe fever with thrombocytopenia
syndrome: an immunohistochemical finding in a fatal case. Virol J. 2018;15(1):97.

20. Bopp NE, Kaiser JA, Strother AE, et al. Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development. NPJ Vaccines. 2020;5(1):111.

21. Liu Y, Wu B, Paessler S, Walker DH, Tesh RB, Yu XJ. The pathogenesis of severe fever with thrombocytopenia syndrome virus infection in alpha/beta interferon knockout mice: insights into the pathologic mechanisms of a new viral hemorrhagic fever. J Virol. 2014;88(3):1781-1786.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments

We acknowledge Dr. Wang Gang for support with the statistical data analysis.

Funding

This study had no funding.

Author information

Affiliations

Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China

Yin Zhang, Yu Zhang, Yuanhong Xu, Ying Huang

contributions

Yin Zhang designed this investigation. Yin Zhang and Yu Zhang collected the original data. Yin Zhang contributed to the statistical analysis of data. Yin Zhang contributed to the writing of the paper. YH and YX contributed to the modification of the paper.

Corresponding author

Correspondence to Yinghuang

Ethics declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
Figure 1

Inflammatory factors in blood and FPG among the three groups
Figure 2

Correlation analysis of inflammatory factors, platelet, and FPG level